# Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH

> **NCT06039124** · — · COMPLETED · sponsor: **Hospices Civils de Lyon** · enrollment: 23 (actual)

## Conditions studied

- Hemorrhagic Hereditary Telangiectasia
- HHT

## Interventions

- **OTHER:** bevacizumab treatment

## Key facts

- **NCT ID:** NCT06039124
- **Lead sponsor:** Hospices Civils de Lyon
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-01
- **Primary completion:** 2022-01-01
- **Final completion:** 2022-08-01
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2023-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06039124

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06039124, "Subsequent Bevacizumab Treatment in Patients With HHT. Follow up BABH". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06039124. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*